Arkolith/Insider Trading/IGC/Form 4

Prins Richard K

DirectorIGC Pharma, Inc. (IGC) · full profile →Form 4 · filed Jun 27, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
7
2 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 31, 2023Option exercise(M)58K—$0913K
Mar 31, 2023Option exercise(M)100K—$0855K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 20, 2023Grant(A)285K—$01.3M
Jun 20, 2023Grant(A)300K—$01.1M
Mar 31, 2023Option exercise(M)58K—$0117K
Mar 31, 2023Option exercise(M)100K—$0100K
May 25, 2022Grant(A)175K—$0175K

Transaction Codes

M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001185185-23-000666) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for IGC Pharma, Inc.

Build

Ask your agent about IGC insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001185185-23-000666"
Ask your agent
Use Arkolith to summarize insider buying and selling at IGC Pharma, Inc.
over the last 90 days and cite the filings.